Mexican women with family history more likely to have triple-negative breast cancer vs. other types
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of California San Diego Moores Cancer Center in La Jolla, California, have found that patients of Mexican descent with breast cancer who had a family history of breast or ovarian cancer were nearly two times as likely to have triple negative breast cancer than other types of breast cancer.
For the study, researchers identified 1,150 women of Mexican descent with breast cancer, 14.9% of whom reported having a first-degree relative with breast or ovarian cancer. They found that women with a first-degree relative who had one of those cancers were nearly twice as likely to be diagnosed with triple-negative breast cancer compared with other types of breast cancer.
The findings suggest that there will be implications in regard to prevention, screening, and treatment of women of Mexican descent with a family history of breast or ovarian cancer. Triple negative breast cancer is often associated with poor outcomes because it lacks the targets for common treatments.
Now, the researchers are investigating whether BRCA mutations are the cause of the association between family history and triple-negative breast cancer that was observed in this study.
Patients of Mexican descent with breast cancer and family history nearly two times as likely to have triple negative breast cancer.
Breast cancer patients of Mexican descent who had a family history of breast or ovarian cancer were almost twice as likely to have triple-negative breast cancer than other subtypes of breast cancer, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
"Triple-negative breast cancer is one of the worst breast cancer subtypes in terms of outcomes," said Maria Elena Martinez, PhD, the Sam M. Walton endowed chair for cancer research and a professor in the Department of Family and Preventive Medicine at the University of California San Diego Moores Cancer Center in La Jolla.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Apalutamide Prolongs Time to Metastasis in Castration-resistant Prostate Cancer
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|